CJC-1295 vs Pasireotide
Overview
CJC-1295 is primarily a performance & growth peptide, while Pasireotide is used for hormonal.
This page compares CJC-1295 and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| CJC-1295 | Pasireotide | |
|---|---|---|
| Category | Performance & Growth | Hormonal |
| Regulatory status (US) | Research use only | FDA approved |
| Typical dosage | 1-2 mg | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | weekly | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Increased muscle mass, fat loss, improved recovery, better sleep, enhanced bone density | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Water retention, joint pain, potential insulin resistance with prolonged use | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. CJC-1295 is categorised under Performance & Growth, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. CJC-1295: not FDA-approved; treated as a research compound. Pasireotide: FDA-approved.
Dosing. CJC-1295 is typically dosed at 1-2 mg (weekly). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking CJC-1295 and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between CJC-1295 and Pasireotide?
- CJC-1295 is primarily a performance & growth peptide, while Pasireotide is used for hormonal. CJC-1295 is not FDA-approved; generally classified as a research compound, whereas Pasireotide is FDA-approved for one or more indications.
- What is CJC-1295 used for?
- Growth hormone, muscle mass, fat loss.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take CJC-1295 and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking CJC-1295 and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is CJC-1295 or Pasireotide FDA-approved?
- CJC-1295 is not FDA-approved; generally classified as a research compound. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- CJC-1295 — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references